RiboNova is a biopharmaceutical company in the Lankenau Institute for Medical Research near Philadelphia. We are developing new medicines for serious rare diseases for which there are no FDA-approved therapies.  
Our product pipeline includes a new drug that is about to enter a Phase 2 clinical study. RiboNova also has a proprietary drug discovery platform for novel precision medicines that target ribonucleic acid.